TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: insulin sensitivity parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: muscle mass preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of atrial-fibrillation or atrial flutter related adverse event at 5 days
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of atrial-fibrillation or atrial flutter related adverse event within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Rivaroxaban plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma eicosapentaenoic acid (EPA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change in Positive Left Ventricular (LV) dP/dt Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting and post prandial blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental State Examination (MMSE) change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Current stress of clinical staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy in performing stroke self-management behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Knowledge and Awareness About Vaccine-Preventable Diseases
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevention of hemodynamically significant PDA (hs-PDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-prandial levels of provitamin A and vitamin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Individualized Prevention Program participation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum observed plasma concentration (Cmax) of Symbicort pMDI administered with spacer device without charcoal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t) of Symbicort pMDI administered with spacer device without charcoal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Awakenings After Sleep Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: positivity of the viral PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute difference in arm volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes under anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power of Attention Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuity of Attention Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postural Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-Rated Alertness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-week all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Locoregional Recurrence-Free Survival (LRRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Biochemically Confirmed Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to quality indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Actual caesarean section rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Recommended calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DWI/IVIM values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the percentage of masses impacting the decision to biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Assessment - Testing Morbidity Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EMS calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric Mean Ratio of Area Under the Plasma Concentration-Time Curve (AUC[0-last]) of Probe Parent Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of Maximum Plasma Concentration (Cmax) of Probe Parent Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Elimination Half-Life in Plasma (t1/2) of Probe Parent Drugs and Their Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Inflammation Burden Scoring (TIBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) of the degree of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lequesne's severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CNVM recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiomyopathy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of the tampon self-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the tampon self-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Complete Healing of the Herpetic Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Lean Body Mass (LBM) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Body Strength (Chest Press Weight) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Blood Testosterone (T) Level at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Biochemical Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in the Yale Global Tic Severity Scale (YGTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse device effects (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal screening rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: improvement in near visual acuity performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood 25 OH D vitamin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stent Thrombosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Rate of Cardiac Death and Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of adverse reactions and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cough severity rated as cough visual analogue score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ovulation With Implant-alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ovulation With Implant and Same Day UPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Shoulder Instability (WOSI) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical failure at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume variation before fluid optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke volume variation after fluid optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of cycles needed to detect a 10% stroke volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of Time to Gastrointestinal Tract Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Partial oxygen pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimally Durable Clinical Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Participants Adherent to Recommended Clinical Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of Excision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Health dietary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tobacco use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Alcohol intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk perception
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Vaccine-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory markers in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival rate regarding absence of spontaneous pain
Endpoint domain: Mortality/survival
Primary endpoint: Influence on the autonomic nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levodopa pharmacokinetics (LD PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of the procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Failure
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of the surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of post-traumatic stress disorder (PTSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reporting Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Duvelisib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Concentration (Tmax) of Duvelisib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of possible adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reversibility of Metabolic Syndrome criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suppression of ovulatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of development of mastitis in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychotic Symptom Rating Scale (PSYRATS) - auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III/IV Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Severe Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: safety of dexmedetomine
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Microbiological Eradication and Clinical Cure at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Microbiological Eradication and Clinical Cure at Test of Cure (TOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery-40 Score at 24 Hours
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Dementia Symptom and Response Knowledge Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Hypersensitive Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity and progression of SG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberrant Behavioral Checklist (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ritvo-Freeman Real Life Scale (RFRLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Independence Measure for Children (WeeFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pediatric Evaluation Disability Inventory (PEDI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Symptom Free Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Elimination of Guselkumab Glycoform Variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple Gated Acquisition (MUGA) assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical lab tests performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved knowledge on under five pneumonia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood pressure brachial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure radial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: body composition measured by Dual Energy X-ray Absorptiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of side effects (morbidity)
Endpoint domain: Adverse events/effects
Primary endpoint: Attachment behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of FEV1 in percentage measured by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intra-operative awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Total Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noninvasive measurement of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMS symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick motor function test (QMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of intradialytic hypotension-associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Delay Discounting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who develop rapid cycling
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in abdominal visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EGFR mutation status (M+, M-)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Status Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Confirmed PSA Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Response During Double-blind Maintenance Phase at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for dynamic variables to predict deflation-induced hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in gene expression of key mediators of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Extrapyramidal Symptoms Rating Scale (ESRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COX-1 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Intensity Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Graft-related Serious Adverse Events (LGRSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: DLT (dose limited toxicity) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Voice intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of c-Met inhibitor AMG 337
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sputum Culture Conversion (2 Negative Cultures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Technical success using the Indigo system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participant's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in patient's partner quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of CDI Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Intracellular and plasma concentration of miltefosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite burden in lesions and extralesional tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiac function - echocardiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported tolerability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of days in hospital within 60 days of surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Altered atrial transcript expression related to NFκB activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of non melanoma skin cancer biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Days With Pain Scores >3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile Reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidences of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sick leave days due to low back pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of cardiac involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Walking Endurance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic Gait Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes